<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="nf2" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">nf2</book-part-id>
      <title-group>
        <title>Neurofibromatosis 2</title>
        <alt-title alt-title-type="alt-title">Synonyms: Bilateral Acoustic Neurofibromatosis, Central Neurofibromatosis, NF2, Neurofibromatosis Type II</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Evans</surname>
            <given-names>D Gareth</given-names>
          </name>
          <degrees>MD, FRCP</degrees>
          <aff>Director, Neurofibromatosis Clinic <break/>Central Manchester Foundation NHS Trust Regional Genetic Service<break/>St Mary's Hospital<break/>Manchester, United Kingdom</aff>
          <email>gareth.evans@cmft.nhs.uk</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>14</day>
          <month>10</month>
          <year>1998</year>
        </date>
        <date date-type="updated">
          <day>18</day>
          <month>8</month>
          <year>2011</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="nf1" document-type="chapter">Neurofibromatosis 1</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="ncl" document-type="chapter">Neuronal Ceroid-Lipofuscinoses</related-object>
      <abstract id="nf2.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Neurofibromatosis 2 (NF2) is characterized by bilateral vestibular schwannomas with associated symptoms of tinnitus, hearing loss, and balance dysfunction. The average age of onset is 18 to 24 years. Almost all affected individuals develop bilateral vestibular schwannomas by age 30 years. Affected individuals may also develop schwannomas of other cranial and peripheral nerves, meningiomas, ependymomas, and, very rarely, astrocytomas. Posterior subcapsular lens opacities that rarely progress to a visually significant cataract are the most common ocular findings and may be the first sign of NF2. Mononeuropathy that occurs in childhood is an increasingly recognized finding; it frequently presents as a persistent facial palsy, a squint (third nerve palsy), or hand/foot drop.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Diagnosis of NF2 is based on clinical criteria. <italic toggle="yes">NF2</italic> is the only gene in which pathogenic variants are known to cause neurofibromatosis 2. Molecular genetic testing of <italic toggle="yes">NF2</italic> that includes a combination of sequence analysis or scanning for pathogenic variants and duplication/deletion testing detects a pathogenic variant in most affected individuals who have a positive family history and are not the first individual in the family known to have the disorder.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Treatment of vestibular schwannoma is primarily surgical; stereotactic radiosurgery, most commonly with the gamma knife, may be an alternative to surgery. Individuals with vestibular tumors need to be aware of insidious problems with balance and underwater disorientation, which can result in drowning. Treatment for hearing loss includes referral to an audiologist, lip-reading and sign language instruction, and possibly hearing aids and/or cochlear or brain stem implants.</p>
          <p><italic toggle="yes">Surveillance:</italic> For affected or at-risk individuals: annual MRI beginning at approximately age ten to 12 years and continuing until at least the fourth decade of life; hearing evaluation, including BAER testing.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Radiation therapy of NF2-associated tumors, especially in childhood, may induce, accelerate, or transform tumors.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Early identification of relatives who have inherited the family-specific <italic toggle="yes">NF2</italic> pathogenic variant allows for appropriate surveillance, resulting in earlier detection and treatment of disease manifestations.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>NF2 is inherited in an autosomal dominant manner. Approximately 50% of individuals with NF2 have an affected parent, and 50% have NF2 as the result of a <italic toggle="yes">de novo</italic> pathogenic variant. However, 25% to 30% of simplex cases (i.e., single occurrence in a family) are mosaic for an <italic toggle="yes">NF2</italic> pathogenic variant. If the proband has other affected family members, each child of the proband has a 50% chance of inheriting the pathogenic variant. Prenatal testing for pregnancies at increased risk is possible if the family-specific pathogenic variant is known or linkage has been established in the family.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="nf2.Diagnosis">
        <title>Diagnosis</title>
        <sec id="nf2.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>Modifications to NIH consensus diagnostic criteria for neurofibromatosis 2 (NF2) have been suggested to enable earlier diagnosis of a founder (i.e., the individual in the first generation of a family known to be affected). These clinical diagnostic criteria for NF2 have been found to improve sensitivity substantially without affecting specificity [<xref ref-type="bibr" rid="nf2.REF.baser.2002.715">Baser et al 2002</xref>]. According to the modified criteria, NF2 is diagnosed in individuals with <bold>one of the following</bold>:</p>
          <list list-type="bullet">
            <list-item>
              <p>Bilateral vestibular schwannomas</p>
            </list-item>
            <list-item>
              <p>A first-degree relative with NF2 <bold>AND</bold></p>
              <list list-type="bullet">
                <list-item>
                  <p>Unilateral vestibular schwannoma <bold>OR</bold></p>
                </list-item>
                <list-item>
                  <p>Any two of: meningioma, schwannoma, glioma, neurofibroma, posterior subcapsular lenticular opacities&#x000a0;*</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Unilateral vestibular schwannoma <bold>AND</bold> any two of: meningioma, schwannoma, glioma, neurofibroma, posterior subcapsular lenticular opacities&#x000a0;*</p>
            </list-item>
            <list-item>
              <p>Multiple meningiomas <bold>AND</bold></p>
              <list list-type="bullet">
                <list-item>
                  <p>Unilateral vestibular schwannoma <bold>OR</bold></p>
                </list-item>
                <list-item>
                  <p>Any two of: schwannoma, glioma, neurofibroma, cataract&#x000a0;*</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>* Any two of = two individual tumors or cataract</p>
        </sec>
        <sec id="nf2.Testing">
          <title>Testing</title>
          <p><bold>Chromosome analysis.</bold> A variety of chromosome abnormalities can be associated with NF2; however, gross chromosomal changes detectable on normal cytogenetic analysis are fairly uncommon.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Cytogenetically visible deletions</bold> encompassing <italic toggle="yes">NF2</italic> may cause intellectual disability and can cause congenital abnormalities [<xref ref-type="bibr" rid="nf2.REF.barbi.2002.e6">Barbi et al 2002</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Ring chromosome 22</bold> can also cause multiple meningiomas and vestibular schwannomas fulfilling NF2 diagnostic criteria [<xref ref-type="bibr" rid="nf2.REF.tsilchorozidou.2004.529">Tsilchorozidou et al 2004</xref>]. The NF2 locus itself is usually present within the ring, but the ring itself is frequently lost as a result of instability.</p>
            </list-item>
            <list-item>
              <p><bold>Apparently balanced chromosomal translocations</bold> that disrupt <italic toggle="yes">NF2</italic> have also been described as causing NF2 [<xref ref-type="bibr" rid="nf2.REF.tsilchorozidou.2004.529">Tsilchorozidou et al 2004</xref>].</p>
            </list-item>
          </list>
          <p><bold>Fluorescence in situ hybridization (FISH) analysis</bold>. Smaller deletions that remove multiple exons of <italic toggle="yes">NF2</italic> or the whole gene can also be identified by FISH analysis [<xref ref-type="bibr" rid="nf2.REF.tsilchorozidou.2004.529">Tsilchorozidou et al 2004</xref>].</p>
          <sec id="nf2.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Gene.</bold>
<italic toggle="yes">NF2</italic> is the only gene in which pathogenic variants are known to cause neurofibromatosis 2.</p>
            <p>
              <bold>Clinical testing</bold>
            </p>
            <table-wrap id="nf2.T.summary_of_molecular_genetic_testi" orientation="portrait" position="anchor">
              <label>Table 1. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in Neurofibromatosis 2</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_nf2.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_nf2.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_nf2.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Pathogenic Variants Detected&#x000a0;<sup>2</sup></th>
                    <th id="hd_h_nf2.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Detection Frequency by Test Method&#x000a0;<sup>3,&#x000a0;4</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_nf2.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">NF2</italic>
                    </td>
                    <td headers="hd_h_nf2.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>5</sup> / scanning for pathogenic variants&#x000a0;<sup>6</sup></td>
                    <td headers="hd_h_nf2.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                    <td headers="hd_h_nf2.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">See footnotes 7 and 8</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_nf2.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication testing&#x000a0;<sup>9</sup></td>
                    <td headers="hd_h_nf2.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Partial- and whole-gene deletions&#x000a0;<sup>10</sup></td>
                    <td headers="hd_h_nf2.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">See footnote11</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_nf2.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Linkage analysis&#x000a0;<sup>12</sup></td>
                    <td headers="hd_h_nf2.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                    <td headers="hd_h_nf2.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="nf2.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="nf2" object-id="nf2.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="nf2.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="nf2.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="nf2.TF.1.3">
                  <label>3. </label>
                  <p>The ability of the test method used to detect a variant that is present in the indicated gene</p>
                </fn>
                <fn id="nf2.TF.1.4">
                  <label>4. </label>
                  <p>Variant detection rates are lower in simplex cases and in the person in the first generation of a family to have NF2 because they are more likely to have somatic mosaicism (see <bold>Interpretation of test results</bold>).</p>
                </fn>
                <fn id="nf2.TF.1.5">
                  <label>5. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="nf2.TF.1.6">
                  <label>6. </label>
                  <p>The detection rate using scanning for pathogenic variants is comparable to that of sequence analysis in up to two thirds of cases.</p>
                </fn>
                <fn id="nf2.TF.1.7">
                  <label>7. </label>
                  <p>When scanning for pathogenic variants is combined with deletion/duplication analysis of single exons, the variant detection rate approaches 72% in simplex cases and exceeds 92% for familial cases [<xref ref-type="bibr" rid="nf2.REF.wallace.2004.368">Wallace et al 2004</xref>, <xref ref-type="bibr" rid="nf2.REF.kluwe.2005.384">Kluwe et al 2005</xref>, <xref ref-type="bibr" rid="nf2.REF.evans.2007b.424">Evans et al 2007b</xref>, <xref ref-type="bibr" rid="nf2.REF.evans.2009.599">Evans 2009</xref>].</p>
                </fn>
                <fn id="nf2.TF.1.8">
                  <label>8. </label>
                  <p>Other studies have reported lower variant detection rates, which may reflect the inclusion of some more mildly affected individuals with somatic mosaicism. Approximately 25% to 33% of pathogenic variants are not detected as a result of somatic mosaicism [<xref ref-type="bibr" rid="nf2.REF.kluwe.2003.109">Kluwe et al 2003</xref>, <xref ref-type="bibr" rid="nf2.REF.moyhuddin.2003.459">Moyhuddin et al 2003</xref>]. Pathogenic variants with mosaicism levels greater than 10% can be detected in lymphocyte DNA [<xref ref-type="bibr" rid="nf2.REF.evans.2007b.424">Evans et al 2007b</xref>]. Identification of the remainder of mosaic pathogenic variants usually requires testing of tumor material [<xref ref-type="bibr" rid="nf2.REF.evans.2007b.424">Evans et al 2007b</xref>] (see <bold>Interpretation of test results</bold>).</p>
                </fn>
                <fn id="nf2.TF.1.9">
                  <label>9. </label>
                  <p>Testing that identifies exon or whole-gene deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
                <fn id="nf2.TF.1.10">
                  <label>10. </label>
                  <p>Most large deletions and, less commonly, duplications of single or multiple exons can be detected by MLPA [<xref ref-type="bibr" rid="nf2.REF.kluwe.2005.384">Kluwe et al 2005</xref>, <xref ref-type="bibr" rid="nf2.REF.evans.2007b.424">Evans et al 2007b</xref>].</p>
                </fn>
                <fn id="nf2.TF.1.11">
                  <label>11. </label>
                  <p>At least 10% to 15% of <italic toggle="yes">NF2</italic> constitutional aberrations are deletions ranging in size from 10 to 600 kb [<xref ref-type="bibr" rid="nf2.REF.zucmanrossi.1998.2095">Zucman-Rossi et al 1998</xref>, <xref ref-type="bibr" rid="nf2.REF.wallace.2004.368">Wallace et al 2004</xref>, <xref ref-type="bibr" rid="nf2.REF.kluwe.2005.384">Kluwe et al 2005</xref>]. However, in inherited cases they make up approximately 20%, boosting sensitivity of the combination of sequence analysis and deletion/duplication testing to 93% (101/108) [<xref ref-type="bibr" rid="nf2.REF.evans.2009.599">Evans 2009</xref>].</p>
                </fn>
                <fn id="nf2.TF.1.12">
                  <label>12. </label>
                  <p>Linkage analysis can be considered in families in whom no pathogenic variant is identified and at least two family members of different generations are affected. Linkage studies are based on an accurate clinical diagnosis of NF2 in the affected family members and accurate understanding of genetic relationships in the family. Linkage analysis depends on the availability and willingness of family members to be tested. The markers used for linkage analysis of <italic toggle="yes">NF2</italic> are highly informative and very tightly linked to <italic toggle="yes">NF2</italic>; thus, they can be used in more than 95% of families with NF2 with greater than 99% accuracy. Linkage testing is not usually available to families with a single affected individual, a situation that often occurs when an individual has a <italic toggle="yes">de novo</italic> variant and no affected offspring; however, modified linkage analysis using both constitutional and tumor DNA can exclude NF2 in those offspring of a simplex case who have not inherited the allele lost in the tumor [<xref ref-type="bibr" rid="nf2.REF.kluwe.2005.384">Kluwe et al 2005</xref>, <xref ref-type="bibr" rid="nf2.REF.evans.2007b.424">Evans et al 2007b</xref>].</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p>
              <bold>Interpretation of test results</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Research has shown that as many as 25% to 33% of individuals with NF2 caused by a <italic toggle="yes">de novo</italic> pathogenic variant have somatic mosaicism for the variant [<xref ref-type="bibr" rid="nf2.REF.kluwe.2003.109">Kluwe et al 2003</xref>, <xref ref-type="bibr" rid="nf2.REF.moyhuddin.2003.459">Moyhuddin et al 2003</xref>, <xref ref-type="bibr" rid="nf2.REF.evans.2007b.424">Evans et al 2007b</xref>]. Recognition of individuals who have somatic mosaicism for an <italic toggle="yes">NF2</italic> pathogenic variant can be difficult because these individuals:</p>
                <list list-type="bullet">
                  <list-item>
                    <p>May not have bilateral vestibular schwannomas [<xref ref-type="bibr" rid="nf2.REF.evans.2008.92">Evans et al 2008</xref>];</p>
                  </list-item>
                  <list-item>
                    <p>May have normal molecular genetic testing of <italic toggle="yes">NF2</italic> in unaffected tissue, such as lymphocytes; thus, molecular genetic testing of tumor tissue may be necessary to establish the presence of somatic mosaicism [<xref ref-type="bibr" rid="nf2.REF.mohyuddin.2002.315">Mohyuddin et al 2002</xref>, <xref ref-type="bibr" rid="nf2.REF.evans.2007b.424">Evans et al 2007b</xref>].</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p>A parent can be excluded as having NF2 if his/her offspring is shown to have somatic mosaicism for an <italic toggle="yes">NF2</italic> pathogenic variant. Absence of an <italic toggle="yes">NF2</italic> pathogenic variant in an offspring does not eliminate the possibility of somatic mosaicism for an <italic toggle="yes">NF2</italic> pathogenic variant in the offspring or parent.</p>
              </list-item>
            </list>
          </sec>
        </sec>
        <sec id="nf2.Testing_Strategy">
          <title>Testing Strategy</title>
          <p><bold>To confirm/establish the diagnosis in a proband.</bold> One of two sample types is used:</p>
          <list list-type="bullet">
            <list-item>
              <p>Leukocyte DNA from an individual who has an affected parent</p>
            </list-item>
            <list-item>
              <p>Tumor DNA from an individual who represents a simplex case</p>
            </list-item>
          </list>
          <p>Molecular genetic testing to detect a germline pathogenic variant is performed in the following order:</p>
          <list list-type="order">
            <list-item>
              <label>1</label>
              <p>Testing for large deletions using a technique such as MLPA</p>
            </list-item>
            <list-item>
              <label>2</label>
              <p>Sequence analysis of exons 1-15 (Pathogenic variants in exons 16-17 have never been described.)</p>
            </list-item>
          </list>
          <p>When tumor DNA is tested, pathogenic variants in both <italic toggle="yes">NF2</italic> alleles must be identified:</p>
          <list list-type="bullet">
            <list-item>
              <p>This may mean testing for loss (or inactivation) of one <italic toggle="yes">NF2</italic> allele by assessing for loss of heterozygosity (LOH).</p>
            </list-item>
            <list-item>
              <p>Once both <italic toggle="yes">NF2</italic> mutated alleles are identified in the tumor, leukocyte DNA can be tested to determine which of the pathogenic variants is constitutional and which is somatic (i.e., present in the tumor only).</p>
            </list-item>
          </list>
          <p>
            <bold>Predictive testing</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At-risk relatives whose genetic status is unknown can be tested for presence of the <italic toggle="yes">NF2</italic> pathogenic variant (either constitutional or somatic mosaic) identified in an affected relative (e.g., the proband).</p>
            </list-item>
            <list-item>
              <p>In the rare instance in which an <italic toggle="yes">NF2</italic> pathogenic variant cannot be identified, linkage analysis can be used in families with at least two affected family members of different generations or tumor DNA can be used to clarify the genetic status of offspring of a simplex case.</p>
            </list-item>
          </list>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variant in the family.</p>
        </sec>
      </sec>
      <sec id="nf2.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="nf2.Clinical_Description">
          <title>Clinical Description</title>
          <p>The average age of onset of findings in individuals with neurofibromatosis 2 (NF2) is 18 to 24 years (onset range: birth to 70 years). Almost all affected individuals develop bilateral vestibular schwannomas by age 30 years. In addition to vestibular schwannoma, individuals with NF2 develop schwannomas of other cranial and peripheral nerves, meningiomas, ependymomas, and, very rarely, astrocytomas.</p>
          <p>Variable expressivity of NF2 among individuals results in varying size, location, and number of tumors. Although these tumors are not malignant, their anatomical location and multiplicity lead to great morbidity and early mortality. The average age of death is 36 years. Actuarial survival from the time of establishing the correct diagnosis is 15 years. Survival is improving with earlier diagnosis and better treatment in specialty centers [<xref ref-type="bibr" rid="nf2.REF.baser.2002.715">Baser et al 2002</xref>, <xref ref-type="bibr" rid="nf2.REF.evans.2005a.5">Evans et al 2005a</xref>].</p>
          <p>Because NF2 is considered an adult-onset disease, it may be under-recognized in children, in whom skin tumors and ocular findings may be the first manifestations [<xref ref-type="bibr" rid="nf2.REF.evans.1999.496">Evans et al 1999</xref>, <xref ref-type="bibr" rid="nf2.REF.ruggieri.2005.21">Ruggieri et al 2005</xref>]. The presenting symptoms of 120 individuals with NF2 studied by <xref ref-type="bibr" rid="nf2.REF.evans.1992.603">Evans et al [1992]</xref> in Great Britain are listed in <xref ref-type="table" rid="nf2.T.presenting_symptoms_of_120_individ">Table 2</xref>. (This study did not include skin tumors or cataracts as a first symptom.)</p>
          <table-wrap id="nf2.T.presenting_symptoms_of_120_individ" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Presenting Symptoms of 120 Individuals with NF2</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Symptom</th>
                  <th id="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">% of Affected Individuals</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Unilateral hearing loss</td>
                  <td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">35%</td>
                </tr>
                <tr>
                  <td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Focal weakness&#x000a0;<sup>1</sup></td>
                  <td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">12%</td>
                </tr>
                <tr>
                  <td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Tinnitus</td>
                  <td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">10%</td>
                </tr>
                <tr>
                  <td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Bilateral hearing loss</td>
                  <td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">9%</td>
                </tr>
                <tr>
                  <td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Balance dysfunction</td>
                  <td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">8%</td>
                </tr>
                <tr>
                  <td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Seizure</td>
                  <td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">8%</td>
                </tr>
                <tr>
                  <td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Focal sensory loss</td>
                  <td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">6%</td>
                </tr>
                <tr>
                  <td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Blindness</td>
                  <td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1%</td>
                </tr>
                <tr>
                  <td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">No symptom, but detected on screening because a parent was affected</td>
                  <td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">11%</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Adapted from <xref ref-type="bibr" rid="nf2.REF.evans.1992.603">Evans et al [1992]</xref></p>
              </fn>
              <fn id="nf2.TF.2.1">
                <label>1. </label>
                <p>Can result from spinal tumors, mononeuropathy, or polyneuropathy</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Vestibular schwannoma.</bold> Initial symptoms include tinnitus, hearing loss, and balance dysfunction. Onset of disability is usually insidious, although occasionally hearing loss may occur suddenly, presumably as a result of vascular compromise by the tumor. Affected individuals often report difficulty in using the telephone in one ear or unsteadiness when walking at night or on uneven ground.</p>
          <p>With time, vestibular tumors extend medially into the cerebellar pontine angle and, if left untreated, cause compression of the brain stem and hydrocephalus. Significant facial palsy is rare even in large tumors.</p>
          <p>Schwannomas may also develop on other cranial and peripheral nerves, with sensory nerves more frequently affected than motor nerves.</p>
          <p><bold>Spinal tumors.</bold> At least two thirds of individuals with NF2 develop spinal tumors, which are often the most devastating and difficult to manage [<xref ref-type="bibr" rid="nf2.REF.dow.2005.574">Dow et al 2005</xref>]. The most common spinal tumors are schwannomas, which usually originate within the intravertebral canal on the dorsal root and extend both medially and laterally, taking the shape of a "dumbbell." Intramedullary tumors of the spinal cord, such as astrocytoma and ependymoma, occur in 5% to 33% of individuals with NF2. Most persons with spinal cord involvement have multiple tumors. Although multiple tumors are often present on imaging studies, they remain asymptomatic in many individuals.</p>
          <p><bold>Meningioma.</bold> Approximately half of individuals with NF2 have meningiomas in cross-sectional studies [<xref ref-type="bibr" rid="nf2.REF.goutagny.2010.341">Goutagny &#x00026; Kalamarides 2010</xref>]; however, lifetime risk may approach 80% [<xref ref-type="bibr" rid="nf2.REF.smith.2011.261">Smith et al 2011</xref>]. Most are intracranial; however, spinal meningiomas occur. NF2 meningiomas tend to occur less frequently in the skull base than supratentorially and are usually of the fibroblastic variety [<xref ref-type="bibr" rid="nf2.REF.evans.2000.897">Evans et al 2000</xref>, <xref ref-type="bibr" rid="nf2.REF.kros.2001.367">Kros et al 2001</xref>]. Meningiomas in the orbit may compress the optic nerve and result in visual loss. Those at the skull base may cause cranial neuropathy, brain stem compression, and hydrocephalus. Meningioma may be the presenting feature of NF2, particularly in childhood [<xref ref-type="bibr" rid="nf2.REF.evans.1999.496">Evans et al 1999</xref>, <xref ref-type="bibr" rid="nf2.REF.perry.2001.994">Perry et al 2001</xref>].</p>
          <p>See <xref ref-type="sec" rid="nf2.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</xref>.</p>
          <p><bold>Ocular involvement.</bold> One third of individuals with NF2 have decreased visual acuity in one or both eyes. Posterior subcapsular lens opacity rarely progressing to a visually significant cataract is the most common ocular finding. Lens opacities may appear prior to the onset of symptoms from vestibular schwannoma and can be seen in children. Cataracts can be present at birth and in these children amblyopia is common in the formative years [<xref ref-type="bibr" rid="nf2.REF.feucht.2008.882">Feucht et al 2008</xref>].</p>
          <p>Retinal hamartoma and epiretinal membrane are seen in up to one third of individuals. Rarely, other ocular manifestations may occur: persistent hyperplastic primary vitreous (PHPV) has been reported in a father and son [<xref ref-type="bibr" rid="nf2.REF.nguyen.2005.247">Nguyen et al 2005</xref>]. In adulthood particular problems with the cornea can occur, especially after surgery that results in the loss of facial, trigeminal, and intermedius nerve function.</p>
          <p>Intracranial and intraorbital tumors may result in decreased visual acuity and diplopia.</p>
          <p><bold>Mono-/polyneuropathy.</bold> A recognized feature of NF2 is a mononeuropathy occurring particularly in childhood [<xref ref-type="bibr" rid="nf2.REF.evans.1999.496">Evans et al 1999</xref>] and frequently presenting as a facial palsy that usually only partially recovers, a squint (third nerve palsy), or a foot or hand drop. The foot drop may mimic polio.</p>
          <p>A progressive polyneuropathy of adulthood not directly related to tumor masses is also recognized [<xref ref-type="bibr" rid="nf2.REF.sperfeld.2002.996">Sperfeld et al 2002</xref>].</p>
          <p>Further evidence for the mononeuropathy of childhood and the polyneuropathy of adulthood has come from sural nerve biopsies [<xref ref-type="bibr" rid="nf2.REF.hagel.2002.179">Hagel et al 2002</xref>].</p>
          <p><bold>Other.</bold> Renal vascular disease similar to that occurring in neurofibromatosis type 1 (NF1) has been reported once [<xref ref-type="bibr" rid="nf2.REF.cordeiro.2006.58">Cordeiro et al 2006</xref>].</p>
          <p><bold>Somatic mosaicism for pathogenic variants in <italic toggle="yes">NF2</italic>.</bold> Mosaicism has been suspected in individuals with unilateral vestibular schwannoma and multiple other, often ipsilateral, tumors [<xref ref-type="bibr" rid="nf2.REF.moyhuddin.2003.459">Moyhuddin et al 2003</xref>, <xref ref-type="bibr" rid="nf2.REF.evans.2008.92">Evans et al 2008</xref>]. This has now been confirmed for most cases in which DNA from multiple tumors has been analyzed [<xref ref-type="bibr" rid="nf2.REF.moyhuddin.2003.459">Moyhuddin et al 2003</xref>, <xref ref-type="bibr" rid="nf2.REF.wallace.2004.368">Wallace et al 2004</xref>, <xref ref-type="bibr" rid="nf2.REF.aghi.2006.201">Aghi et al 2006</xref>, <xref ref-type="bibr" rid="nf2.REF.evans.2008.92">Evans et al 2008</xref>].</p>
          <p><bold>Histopathology.</bold> The tumors of NF2 are derived from Schwann cells, meningeal cells, and glial cells. They are uniformly benign. Approximately 40% of NF2 vestibular tumors have a lobular pattern that is uncommon in tumors from individuals who have no known family history of NF2.</p>
          <list list-type="bullet">
            <list-item>
              <p>NF2-associated vestibular schwannomas tend to be more invasive and to have a higher degree of dividing cells than non-NF2 tumors.</p>
            </list-item>
            <list-item>
              <p>NF2-associated meningiomas have a higher degree of dividing cells than non-NF2 meningiomas. NF2 meningiomas are usually of the fibroblastic variety.</p>
            </list-item>
            <list-item>
              <p>No histologic differences have been observed between glial tumors in individuals with NF2 and individuals who do not have NF2.</p>
            </list-item>
          </list>
        </sec>
        <sec id="nf2.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Intrafamilial variability is much lower than interfamilial variability, suggesting a strong effect of the underlying genotype on the resulting phenotype.</p>
          <p>Unlike <related-object link-type="booklink" source-id="gene" document-id="nf1" document-type="chapter">neurofibromatosis type 1</related-object> (NF1), large deletions of <italic toggle="yes">NF2</italic> have been associated with a mild phenotype [<xref ref-type="bibr" rid="nf2.REF.baser.2004.231">Baser et al 2004</xref>]. At least 10% to 15% of <italic toggle="yes">NF2</italic> constitutional aberrations are deletions ranging in size from 10 to 600 kb [<xref ref-type="bibr" rid="nf2.REF.zucmanrossi.1998.2095">Zucman-Rossi et al 1998</xref>, <xref ref-type="bibr" rid="nf2.REF.wallace.2004.368">Wallace et al 2004</xref>, <xref ref-type="bibr" rid="nf2.REF.kluwe.2005.384">Kluwe et al 2005</xref>]; even if quite large, these deletions are not associated with intellectual disability.</p>
          <p>The type of <italic toggle="yes">NF2</italic> constitutional pathogenic variant is an important determinant of the number of NF2-associated intracranial meningiomas, spinal tumors, and peripheral nerve tumors [<xref ref-type="bibr" rid="nf2.REF.baser.2004.231">Baser et al 2004</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Nonsense and frame-shifting variants have been associated with severe disease regardless of their position within the gene [<xref ref-type="bibr" rid="nf2.REF.baser.2004.231">Baser et al 2004</xref>].</p>
            </list-item>
            <list-item>
              <p>Splice site variants have been associated with both mild and severe disease [<xref ref-type="bibr" rid="nf2.REF.kluwe.1998.228">Kluwe et al 1998</xref>, <xref ref-type="bibr" rid="nf2.REF.baser.2005.540">Baser et al 2005</xref>] and may be milder if occurring in the 3' half of the gene [<xref ref-type="bibr" rid="nf2.REF.baser.2005.540">Baser et al 2005</xref>].</p>
            </list-item>
            <list-item>
              <p>Missense variants are usually mild, often causing the mildest form of NF2 [<xref ref-type="bibr" rid="nf2.REF.evans.1998a.450">Evans et al 1998a</xref>, <xref ref-type="bibr" rid="nf2.REF.baser.2002.715">Baser et al 2002</xref>].</p>
            </list-item>
            <list-item>
              <p>Truncating variants are associated with earlier onset and greater number of NF2-associated intracranial meningiomas, spinal tumors, and peripheral nerve tumors. In general, truncating variants (frameshift and nonsense) are associated with greater disease-related mortality than missense and splice site variants or deletions [<xref ref-type="bibr" rid="nf2.REF.baser.2002.715">Baser et al 2002</xref>, <xref ref-type="bibr" rid="nf2.REF.baser.2005.540">Baser et al 2005</xref>]. Truncating variants are also associated with increased prevalence of spinal tumors [<xref ref-type="bibr" rid="nf2.REF.patronas.2001.434">Patronas et al 2001</xref>, <xref ref-type="bibr" rid="nf2.REF.dow.2005.574">Dow et al 2005</xref>]. Although most of these pathogenic variants would be predicted to result in nonsense-mediated decay and, thus, no protein product, the apparent dominant negative affect of these variants requires further investigation.</p>
            </list-item>
            <list-item>
              <p>Pathogenic variants in the 3&#x02019; half of <italic toggle="yes">NF2</italic> (especially those in exons 14-16) are associated with lower risk of meningioma than pathogenic variants in the 5&#x02019; half of the gene [<xref ref-type="bibr" rid="nf2.REF.smith.2011.261">Smith et al 2011</xref>] (see <xref ref-type="fig" rid="nf2.F1">Figure 1</xref>).</p>
            </list-item>
          </list>
          <p>Somatic mosaicism (even when detected in lymphocyte DNA) for typical pathogenic truncating variants that would normally cause severe NF2 may result in a milder phenotype [<xref ref-type="bibr" rid="nf2.REF.evans.1998a.450">Evans et al 1998a</xref>, <xref ref-type="bibr" rid="nf2.REF.evans.2007b.424">Evans et al 2007b</xref>].</p>
        </sec>
        <sec id="nf2.Penetrance">
          <title>Penetrance</title>
          <p>Penetrance is close to 100%. Virtually all individuals who have a germline pathogenic variant develop the disease in an average lifetime.</p>
          <p>Age at onset can vary with variant type; see <xref ref-type="sec" rid="nf2.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</xref>.</p>
        </sec>
        <sec id="nf2.Anticipation">
          <title>Anticipation</title>
          <p>Although some reports suggested anticipation in NF2, these were likely to be instances of milder disease associated with mosaicism for an <italic toggle="yes">NF2</italic> pathogenic variant in the first generation and more severe disease associated with an <italic toggle="yes">NF2</italic> germline (i.e., constitutional) pathogenic variant in the second and subsequent generations.</p>
        </sec>
        <sec id="nf2.Nomenclature">
          <title>Nomenclature</title>
          <p>The term "neurofibromatosis" is a misnomer because the primary tumor types in NF2 are schwannoma and meningioma. Vestibular schwannoma (previously termed acoustic neuroma) was initially considered part of von Recklinghausen <related-object link-type="booklink" source-id="gene" document-id="nf1" document-type="chapter">neurofibromatosis type 1</related-object>, leading to multiple instances in which individuals with NF2 were included in series of individuals with NF1.</p>
          <p>Since 1987, the great majority of reports have correctly distinguished between NF1 and NF2, with NF2 described as "bilateral acoustic" or "central" neurofibromatosis.</p>
        </sec>
        <sec id="nf2.Prevalence">
          <title>Prevalence</title>
          <p>Initially the incidence of NF2 was reported as 1:33,000-40,000 individuals and the disease prevalence somewhat lower at 1:200,000.</p>
          <p>Based on a 2010 study, the original 1:33,000 estimate of incidence has been confirmed, whereas the estimated prevalence (1:60,000) is higher than originally thought [<xref ref-type="bibr" rid="nf2.REF.evans.2010.327">Evans et al 2010</xref>].</p>
          <p>Note: An update in 2005 erroneously suggested that the incidence may be as high as 1:25,000 [<xref ref-type="bibr" rid="nf2.REF.evans.2005b.93">Evans et al 2005b</xref>].</p>
          <p>NF2 has no ethnic or racial predilections.</p>
        </sec>
      </sec>
      <sec id="nf2.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No other phenotypes are known to be associated with pathogenic variants in <italic toggle="yes">NF2</italic>.</p>
      </sec>
      <sec id="nf2.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><bold>Neurofibromatosis type 1.</bold> Although the two disorders are clinically distinct and caused by pathogenic variants in different genes at different chromosomal loci, diagnostic confusion continues to exist between <related-object link-type="booklink" source-id="gene" document-id="nf1" document-type="chapter">neurofibromatosis type 1</related-object> (NF1) and neurofibromatosis 2 (NF2); thus, it is worth noting several features that distinguish them:</p>
        <list list-type="bullet">
          <list-item>
            <p>Individuals with NF2 do not have the cognitive problems (intellectual disability and learning disability) seen in some individuals with NF1, nor do they have significant numbers of Lisch nodules (i.e., iris hamartomas).</p>
          </list-item>
          <list-item>
            <p>In individuals with NF2, schwannomas rarely, if ever, undergo malignant transformation to neurofibrosarcoma.</p>
          </list-item>
          <list-item>
            <p>Individuals with NF2, contrary to a common misconception, do not have significant numbers of caf&#x000e9; au lait macules, although they are probably more numerous than in the general population.</p>
          </list-item>
          <list-item>
            <p>The dumbbell configuration of the spinal root tumors, which are schwannomas in NF2 and neurofibromas in NF1, may occasionally cause initial diagnostic confusion between the two disorders.</p>
          </list-item>
        </list>
        <p><bold>Schwannomatosis</bold> is defined as multiple schwannomas without the vestibular schwannomas that are diagnostic of NF2 [<xref ref-type="bibr" rid="nf2.REF.maccollin.2005.1838">MacCollin et al 2005</xref>]. Previous terminology for this condition has included multiple neurilemomas, multiple schwannomas, and neurilemomatosis [<xref ref-type="bibr" rid="nf2.REF.maccollin.2005.1838">MacCollin et al 2005</xref>].</p>
        <p>Individuals with schwannomatosis may develop intracranial, spinal nerve root, or peripheral nerve tumors; malignant transformation may rarely occur. One third of individuals with schwannomatosis have anatomically localized tumors suggestive of segmental disease [<xref ref-type="bibr" rid="nf2.REF.maccollin.2005.1838">MacCollin et al 2005</xref>].</p>
        <p>Familial cases appear to be inherited in an autosomal dominant manner, with highly variable expressivity and incomplete penetrance. Schwannomatosis is clinically and genetically distinct from NF1 and NF2, although some individuals with multiple schwannomas eventually fulfill NF2 diagnostic criteria and some simplex cases of schwannomatosis are mosaic for an <italic toggle="yes">NF2</italic> pathogenic variant [<xref ref-type="bibr" rid="nf2.REF.moyhuddin.2003.459">Moyhuddin et al 2003</xref>]. The locus for schwannomatosis had been mapped to an area close to, but excluding, <italic toggle="yes">NF2</italic> [<xref ref-type="bibr" rid="nf2.REF.maccollin.2003.1968">MacCollin et al 2003</xref>]. A pathogenic variant in <italic toggle="yes">SMARCB1</italic> (<italic toggle="yes">INI1</italic>) was identified in a family with schwannomatosis [<xref ref-type="bibr" rid="nf2.REF.hulsebos.2007.805">Hulsebos et al 2007</xref>]. Subsequent analysis has shown that <italic toggle="yes">SMARCB1</italic> pathogenic variants cause 30%-60% of familial schwannomatosis, but only a small percentage of simplex disease (i.e., a single occurrence in a family) [<xref ref-type="bibr" rid="nf2.REF.boyd.2008.358">Boyd et al 2008</xref>, <xref ref-type="bibr" rid="nf2.REF.hadfield.2008.332">Hadfield et al 2008</xref>, <xref ref-type="bibr" rid="nf2.REF.sestini.2008.227">Sestini et al 2008</xref>].</p>
        <p><bold>Unilateral vestibular schwannoma</bold> is a common tumor in the general population, accounting for 5% to 10% of all intracranial tumors and the vast majority of cerebellar pontine angle tumors.</p>
        <p>Approximately 5% of vestibular schwannomas are bilateral [<xref ref-type="bibr" rid="nf2.REF.evans.2005b.93">Evans et al 2005b</xref>] and thus associated with NF2; 95% are unilateral occurrences in individuals who have no underlying genetic predisposition to such tumors. The risk that a unilateral tumor is the first manifestation of NF2 is closely related to the age of the affected individual.</p>
        <list list-type="bullet">
          <list-item>
            <p>Individuals younger than age 30 years, with a symptomatic unilateral vestibular schwannoma, are at high risk of developing a contralateral tumor and NF2 and should be monitored closely. Indeed, approximately 6% of individuals with an apparently isolated vestibular schwannoma are mosaic for an <italic toggle="yes">NF2</italic> pathogenic variant [<xref ref-type="bibr" rid="nf2.REF.mohyuddin.2002.315">Mohyuddin et al 2002</xref>, <xref ref-type="bibr" rid="nf2.REF.evans.2007a.354">Evans et al 2007a</xref>].</p>
          </list-item>
          <list-item>
            <p>Individuals older than age 30 years who have a unilateral vestibular schwannoma are at very low risk of developing NF2 [<xref ref-type="bibr" rid="nf2.REF.evans.2007a.354">Evans et al 2007a</xref>].</p>
          </list-item>
        </list>
        <p>The offspring of individuals with unilateral vestibular schwannoma and no known family history of schwannomas do not have an increased incidence of either NF2 or unilateral vestibular schwannoma. Somatic involvement of <italic toggle="yes">NF2</italic> in isolated vestibular schwannomas is almost universal [<xref ref-type="bibr" rid="nf2.REF.mohyuddin.2002.315">Mohyuddin et al 2002</xref>, <xref ref-type="bibr" rid="nf2.REF.szijan.2003.41">Szijan et al 2003</xref>]; however, it is possible that pathogenic variants in other genes on chromosome 22 predispose to schwannoma development [<xref ref-type="bibr" rid="nf2.REF.mantripragada.2003.615">Mantripragada et al 2003</xref>].</p>
        <p><bold>Meningioma.</bold> Multiple meningiomas typically occur in older adults; thus, the finding of a single meningioma in an individual younger than age 25 years should prompt evaluation for an underlying genetic condition [<xref ref-type="bibr" rid="nf2.REF.evans.2005c.45">Evans et al 2005c</xref>]. Meningiomas may predate the development of vestibular schwannomas, and any childhood meningioma should be considered as a possible early sign of NF2 [<xref ref-type="bibr" rid="nf2.REF.evans.1999.496">Evans et al 1999</xref>, <xref ref-type="bibr" rid="nf2.REF.perry.2001.994">Perry et al 2001</xref>, <xref ref-type="bibr" rid="nf2.REF.evans.2005c.45">Evans et al 2005c</xref>]. Individuals with multiple meningiomas may occasionally be mosaic for an <italic toggle="yes">NF2</italic> pathogenic variant without the presence of vestibular schwannoma; in general, however, adults with multiple meningiomas and no vestibular schwannoma are at low risk for NF2 [<xref ref-type="bibr" rid="nf2.REF.evans.2005c.45">Evans et al 2005c</xref>].</p>
        <p>Rare instances of multiple meningiomas without vestibular schwannoma segregating as an autosomal dominant disorder have been reported [<xref ref-type="bibr" rid="nf2.REF.maxwell.1998.562">Maxwell et al 1998</xref>, <xref ref-type="bibr" rid="nf2.REF.goutagny.2010.341">Goutagny &#x00026; Kalamarides 2010</xref>]. Recently a pathogenic variant in <italic toggle="yes">SMARCB1</italic> that causes a proportion of schwannomatosis was reported in one family [<xref ref-type="bibr" rid="nf2.REF.christiaans.2011.93">Christiaans et al 2011</xref>], but the great majority of individuals with multiple meningioma do not harbor a <italic toggle="yes">SMARCB1</italic> pathogenic variant [<xref ref-type="bibr" rid="nf2.REF.hadfield.2010.567">Hadfield et al 2010</xref>]. Linkage analysis of one affected family has implicated a locus distinct from the <italic toggle="yes">NF2</italic> locus. A gene other than <italic toggle="yes">NF2</italic> is implicated in more than 60% of all meningiomas that occur in individuals with no known family history of meningiomas [<xref ref-type="bibr" rid="nf2.REF.lomas.2005.314">Lomas et al 2005</xref>].</p>
      </sec>
      <sec id="nf2.Management">
        <title>Management</title>
        <sec id="nf2.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease in an individual diagnosed with neurofibromatosis 2 (NF2), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Head MRI</p>
            </list-item>
            <list-item>
              <p>Hearing evaluation, including BAER</p>
            </list-item>
            <list-item>
              <p>Ophthalmologic evaluation</p>
            </list-item>
            <list-item>
              <p>Cutaneous examination</p>
            </list-item>
            <list-item>
              <p>Clinical genetics consultation</p>
            </list-item>
          </list>
          <p>Note: Evaluation and treatment of individuals with neurofibromatosis 2 (NF2) are best undertaken in an NF2 center experienced in managing the multiple complications of the disease [<xref ref-type="bibr" rid="nf2.REF.baser.2002.715">Baser et al 2002</xref>, <xref ref-type="bibr" rid="nf2.REF.evans.2005a.5">Evans et al 2005a</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p>For NF specialists see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ctf.org/understanding-nf/find-doctor">www.ctf.org</ext-link>.</p>
            </list-item>
            <list-item>
              <p>For NF2 service centers in UK see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nfauk.org/what-is-neurofibromatosis/nf-type-2/the-nf2-service-in-uk/">www.nfauk.org</ext-link>.</p>
            </list-item>
          </list>
        </sec>
        <sec id="nf2.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p><bold>Vestibular schwannoma.</bold> Untreated tumors may be slow growing and not require active intervention in the short term [<xref ref-type="bibr" rid="nf2.REF.masuda.2004.150">Masuda et al 2004</xref>, <xref ref-type="bibr" rid="nf2.REF.slattery.2004.811">Slattery et al 2004</xref>]. Therapy remains primarily surgical.</p>
          <list list-type="bullet">
            <list-item>
              <p>Small vestibular tumors (&#x0003c;1.5 mm) that are completely intercanalicular can often be completely resected, with preservation of both hearing and facial nerve function.</p>
            </list-item>
            <list-item>
              <p>Larger tumors are probably best managed expectantly, with debulking or decompression carried out only when brain stem compression, deterioration of hearing, and/or facial nerve dysfunction occur [<xref ref-type="bibr" rid="nf2.REF.evans.2005a.5">Evans et al 2005a</xref>]. However, balancing between early surgery and preservation of facial function and later surgery when a patient is still hearing is difficult [<xref ref-type="bibr" rid="nf2.REF.evans.2005a.5">Evans et al 2005a</xref>].</p>
            </list-item>
          </list>
          <p>Stereotactic radiosurgery, most commonly with the gamma knife, has been offered as an alternative to surgery in select individuals with vestibular schwannoma. However, the outcomes from radiation treatment in individuals with NF2 are not as good as for individuals with sporadic unilateral vestibular schwannoma, with only approximately 60% long-term tumor control [<xref ref-type="bibr" rid="nf2.REF.rowe.2003.1288">Rowe et al 2003</xref>].</p>
          <p>Malignant transformation is a possible, though probably not common, sequela [<xref ref-type="bibr" rid="nf2.REF.baser.2000.998">Baser et al 2000</xref>]; however, it should be noted that tumor development following radiation may take 15 years [<xref ref-type="bibr" rid="nf2.REF.evans.2006.289">Evans et al 2006</xref>]. This may involve development of a malignancy within the treated lesion or a new malignancy (e.g., glioblastoma) in the radiation field [<xref ref-type="bibr" rid="nf2.REF.balasubramaniam.2007.447">Balasubramaniam et al 2007</xref>].</p>
          <p>Management of individuals with vestibular tumors should include counseling for insidious problems with balance and underwater disorientation, which can result in drowning.</p>
          <p><bold>Other tumors.</bold> Other intracranial, cranial nerve, or spinal nerve tumors are very slow growing, and surgical intervention for a tumor producing little impairment may cause disability years before it would occur naturally.</p>
          <p>Although ependymoma in individuals without NF2 is optimally treated with complete resection, and occasionally with radiotherapy and chemotherapy, it is unclear whether ependymoma in individuals with NF2 warrants aggressive management.</p>
          <p>Radiation therapy of NF2-associated tumors should be carefully considered because radiation exposure may induce, accelerate, or transform tumors in an individual (especially a child) with an inactive tumor suppressor gene [<xref ref-type="bibr" rid="nf2.REF.baser.2000.998">Baser et al 2000</xref>, <xref ref-type="bibr" rid="nf2.REF.evans.2006.289">Evans et al 2006</xref>].</p>
          <p><bold>Hearing.</bold> Hearing preservation and augmentation are important in the management of individuals with NF2. All affected individuals and their families should be referred to an audiologist to receive training in optimization of hearing and speech production.</p>
          <list list-type="bullet">
            <list-item>
              <p>Lip-reading skills may be enhanced by instruction.</p>
            </list-item>
            <list-item>
              <p>Sign language may often be more effectively acquired before the individual loses hearing.</p>
            </list-item>
            <list-item>
              <p>Hearing aids may be helpful early in the course of the disease [<xref ref-type="bibr" rid="nf2.REF.evans.2005a.5">Evans et al 2005a</xref>].</p>
            </list-item>
            <list-item>
              <p>Auditory rehabilitation with a cochlear or brain stem implant should be discussed with those who have lost hearing [<xref ref-type="bibr" rid="nf2.REF.evans.2005a.5">Evans et al 2005a</xref>]. Rarely, individuals who have had vascular insult to the cochlea, but otherwise are without nerve damage, may benefit from a cochlear implant.</p>
            </list-item>
          </list>
          <p><bold>Ocular involvement.</bold> Early recognition and management of visual impairment from other manifestations of NF2 are extremely important.</p>
        </sec>
        <sec id="nf2.Prevention_of_Secondary_Complication">
          <title>Prevention of Secondary Complications</title>
          <p>Treatment concentrates on prevention of secondary complications. Prevention of substantial handicap from the disease can be achieved by appropriate expert treatment of tumors:</p>
          <list list-type="bullet">
            <list-item>
              <p>A cervical spinal scan should be performed before cranial surgery to prevent complications from manipulation under anesthesia [<xref ref-type="bibr" rid="nf2.REF.evans.2005a.5">Evans et al 2005a</xref>].</p>
            </list-item>
            <list-item>
              <p>Spinal tumors may make epidural analgesia difficult; therefore, lumbosacral imaging should be performed before regional analgesia is given [<xref ref-type="bibr" rid="nf2.REF.sakai.2005.332">Sakai et al 2005</xref>, <xref ref-type="bibr" rid="nf2.REF.spiegel.2005.336">Spiegel et al 2005</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="nf2.Surveillance">
          <title>Surveillance</title>
          <p>For at-risk individuals (1) in whom the known pathogenic variant in the family has been identified or (2) whose genetic status cannot be clarified by molecular genetic testing:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>MRI</bold> is usually begun between ages ten and 12 years but can be delayed in families in which the onset is known to be later [<xref ref-type="bibr" rid="nf2.REF.evans.2005a.5">Evans et al 2005a</xref>]. MRI should be continued on an annual basis until at least the fourth decade of life. It is not clear if earlier surveillance (i.e., cranial MRI before age 10 years) is beneficial, and it is not known at what age monitoring can be safely stopped. Although some individuals with NF2 do not have symptoms until they are in their fifties, it is likely that "silent" tumors would be detected on an MRI performed at a younger age.</p>
            </list-item>
            <list-item>
              <p><bold>Hearing evaluation,</bold> including BAER testing, may be useful in detecting changes in auditory nerve function before changes can be visualized by MRI.</p>
            </list-item>
          </list>
          <p>Routine complete eye examinations should be part of the care of all individuals with NF2.</p>
        </sec>
        <sec id="nf2.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Radiotherapy should be avoided in children with NF2 [<xref ref-type="bibr" rid="nf2.REF.evans.2006.289">Evans et al 2006</xref>].</p>
        </sec>
        <sec id="nf2.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>Consideration of molecular genetic testing of at-risk family members (see <xref ref-type="sec" rid="nf2.Related_Genetic_Counseling_Issues">Genetic Counseling</xref>) during childhood is appropriate for surveillance:</p>
          <list list-type="bullet">
            <list-item>
              <p>Early identification of relatives who have inherited the family-specific <italic toggle="yes">NF2</italic> pathogenic variant allows for appropriate screening using MRI for neuroimaging and brain stem auditory evoked response (BAER) testing for audiologic evaluation, thus resulting in earlier detection of disease manifestations and improved final outcomes [<xref ref-type="bibr" rid="nf2.REF.evans.2005a.5">Evans et al 2005a</xref>].</p>
            </list-item>
            <list-item>
              <p>Early identification of those who have not inherited the family-specific <italic toggle="yes">NF2</italic> pathogenic variant eliminates the need for costly screening with MRI and BAER testing.</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="nf2.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
          <p>
            <bold>Pregnancy Management</bold>
          </p>
          <p>Although no convincing evidence exists that schwannomas increase in size during pregnancy, hormonal effects on meningiomas are possible; therefore, assessment of the potential risk of increased intracranial pressure is important for women considering pregnancy.</p>
        </sec>
        <sec id="nf2.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>The search for an effective medical treatment for NF2-related tumors continues.</p>
          <p>One of the first groups of agents suggested were PAK1-blocking drugs [<xref ref-type="bibr" rid="nf2.REF.hirokawa.2004.20">Hirokawa et al 2004</xref>]. Targeting the ERK1, AKT, integrin/focal adhesion kinase/Src/Ras signaling cascades, PDGFRbeta, phosphatidylinositol 3-kinase/protein kinase C/Src/c-Raf pathway, VEG-F, and other pathways [<xref ref-type="bibr" rid="nf2.REF.hanemann.2008.606">Hanemann 2008</xref>, <xref ref-type="bibr" rid="nf2.REF.evans.2009.5032">Evans et al 2009</xref>, <xref ref-type="bibr" rid="nf2.REF.blair.2011.308">Blair et al 2011</xref>], drugs such as avastin, elotinib [<xref ref-type="bibr" rid="nf2.REF.plotkin.2008.487">Plotkin et al 2008</xref>], lapatinib, and sorafenib [<xref ref-type="bibr" rid="nf2.REF.ammoun.2008.5236">Ammoun et al 2008</xref>] may well be effective treatments for NF2. These agents could be tried on the <italic toggle="yes">Nf2</italic> mouse model; the first human clinical trials in North America and the UK are also commencing.</p>
          <p>The most promising results have come from short- to medium-term treatment with avastin [<xref ref-type="bibr" rid="nf2.REF.plotkin.2009.358">Plotkin et al 2009</xref>], which seems to have efficacy against rapidly growing schwannomas and possibly ependymomas, although not meningiomas. Further development of treatment trials is underway [<xref ref-type="bibr" rid="nf2.REF.evans.2009.5032">Evans et al 2009</xref>].</p>
          <p>Recently drug trials have identified bevacizumab as a potential treatment [<xref ref-type="bibr" rid="nf2.REF.plotkin.2009.358">Plotkin et al 2009</xref>].</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="nf2.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="nf2.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Neurofibromatosis 2 (NF2) is inherited in an autosomal dominant manner.</p>
        </sec>
        <sec id="nf2.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Approximately 50% of individuals with NF2 have an affected parent, and 50% have NF2 as the result of a <italic toggle="yes">de novo</italic> pathogenic variant. However, 25% to 33% of individuals who are simplex cases (i.e., individuals with no family history of NF2) are mosaic for an <italic toggle="yes">NF2</italic> pathogenic variant [<xref ref-type="bibr" rid="nf2.REF.kluwe.2003.109">Kluwe et al 2003</xref>, <xref ref-type="bibr" rid="nf2.REF.moyhuddin.2003.459">Moyhuddin et al 2003</xref>, <xref ref-type="bibr" rid="nf2.REF.evans.2007b.424">Evans et al 2007b</xref>].</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a proband with an apparent <italic toggle="yes">de novo</italic> pathogenic variant include a clinical history and, if any suspicion of NF2 exists, an MRI scan. The possibility that a parent has NF2 can be excluded if his/her offspring is shown to be mosaic, but absence of a pathogenic variant detected in the child does not eliminate the possibility of mosaicism in the parent. Because the age of onset of symptoms is consistent within families, it is usually not necessary to offer surveillance to asymptomatic parents.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of the proband depends on the genetic status of the parents.</p>
            </list-item>
            <list-item>
              <p>If a parent of the proband is affected, the risk to the sibs is 50%.</p>
            </list-item>
            <list-item>
              <p>If neither parent of an individual with NF2 is symptomatic, the risk to the sibs of the affected individual is low because the age of onset of symptoms is relatively uniform within families. However, a single case of germline mosaicism in a clinically normal parent has been reported. In addition, somatic mosaicism (which may include germline mosaicism) is found in 25%-33% of individuals with NF2 who are simplex cases.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with NF2 has up to a 50% chance of inheriting the pathogenic variant:</p>
          <list list-type="bullet">
            <list-item>
              <p>If the proband has other affected family members, each child of the proband has a 50% chance of inheriting the pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>If the proband is the only affected individual in the family, two possibilities exist:</p>
              <list list-type="bullet">
                <list-item>
                  <p>The proband may have somatic mosaicism for the pathogenic variant. Offspring of an individual who is mosaic may have less than a 50% risk of inheriting the pathogenic variant.</p>
                </list-item>
                <list-item>
                  <p>The proband may have a <italic toggle="yes">de novo</italic> germline pathogenic variant (i.e., present in the egg or sperm at the time of conception). Each offspring of an individual with a <italic toggle="yes">de novo</italic> germline pathogenic variant has a 50% chance of inheriting the variant.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Persons with somatic mosaicism and bilateral vestibular tumors have less than a 50% chance of having an affected child [<xref ref-type="bibr" rid="nf2.REF.evans.1998b.727">Evans et al 1998b</xref>]. If the pathogenic variant is detected in DNA from multiple tumors, but not in DNA from leukocytes, the risk to offspring is probably less than 5%.</p>
            </list-item>
          </list>
          <p><bold>Other family members of a proband.</bold> The risk to other family members depends on the genetic status of the proband's parents. If a parent is affected, his or her family members may be at risk, depending on the family structure.</p>
        </sec>
        <sec id="nf2.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="nf2.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant.</bold> When the parents of a proband with an autosomal dominant condition are unaffected, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p>
          <p><bold>Testing of at-risk asymptomatic family members.</bold> Consideration of molecular genetic testing of at-risk family members during childhood is appropriate for surveillance (see <xref ref-type="sec" rid="nf2.Surveillance">Surveillance</xref>). Molecular genetic testing used in early identification of at-risk family members may be either analysis for pathogenic variants or linkage analysis. Analysis for pathogenic variants can be used for testing of at-risk relatives only if a pathogenic variant has been identified in an affected family member. Linkage analysis is the preferred method of testing in families with more than one affected family member if the family-specific pathogenic variant has not been identified.</p>
          <p>Because early detection of at-risk individuals affects medical management, testing of at-risk asymptomatic individuals younger than age 18 years is beneficial. Parents often want to know the genetic status of their children prior to initiating screening in order to avoid unnecessary procedures for a child who has not inherited the altered gene. Special consideration should be given to education of the children and their parents prior to genetic testing. A plan should be established for the manner in which results are to be given to the parents and children.</p>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="nf2.Prenatal_Testing_and_Preimplantation">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">NF2</italic> pathogenic variant has been identified or linkage has been established in the family, prenatal diagnosis for a pregnancy at increased risk and preimplantation genetic diagnosis for NF2 are possible.</p>
        </sec>
      </sec>
      <sec id="nf2.Resources">
        <title>Resources</title>
      </sec>
      <sec id="nf2.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">NF2</italic> spans 110 kb and comprises 16 constitutive exons and one alternatively spliced exon. <italic toggle="yes">NF2</italic> is widely expressed, producing mRNAs in three different lengths of approximately 7, 4.4, and 2.6 kb. See <related-object source-id="gene" document-id="nf2" object-id="nf2.molgen.TA">Table A</related-object>, <bold>Gene</bold> for a detailed summary of gene and protein information.</p>
        <p><bold>Benign variants.</bold> No frequent benign variants, even in codon wobble positions, have been reported in <italic toggle="yes">NF2</italic>.</p>
        <p><bold>Pathogenic variants.</bold> At least 200 different pathogenic variants in <italic toggle="yes">NF2</italic>, the majority of which are single-nucleotide variants, have been described [<xref ref-type="bibr" rid="nf2.REF.legoix.2000.62">Legoix et al 2000</xref>, <xref ref-type="bibr" rid="nf2.REF.baser.2006.297">Baser 2006</xref>].</p>
        <p>A wide variety of pathogenic variants have been identified in all <italic toggle="yes">NF2</italic> exons, except for the alternatively spliced exons 16 and 17.</p>
        <list list-type="bullet">
          <list-item>
            <p>Ninety percent of single-nucleotide variants are predicted to truncate the protein by introduction of a premature stop codon, a frameshift with premature termination, or a splicing alteration, supporting the view that loss of the protein's normal function is necessary for the development of tumors. C to T transitions in CGA codons causing pathogenic nonsense variants are an especially frequent occurrence.</p>
          </list-item>
          <list-item>
            <p>Fewer than 10% of detected pathogenic variants are in-frame deletions and missense variants, which may indicate that alteration of particular functional domains can abolish the <italic toggle="yes">NF2</italic> tumor suppressor activity [<xref ref-type="bibr" rid="nf2.REF.baser.2006.730">Baser et al 2006</xref>].</p>
          </list-item>
        </list>
        <p><bold>Normal gene product.</bold> The NF2 protein product has been named "merlin" (for <italic toggle="yes">m</italic>oezin-<italic toggle="yes">e</italic>zrin-<italic toggle="yes">r</italic>adixin-<italic toggle="yes">l</italic>ike prote<italic toggle="yes">in</italic>) because of the high homology to the 4.1 family of cytoskeletal associated proteins. Alternatively, the name schwannomin has been proposed in recognition of its role in preventing schwannoma formation.</p>
        <p>All 4.1 family members have a homologous domain of approximately 270 amino acids at the N terminus. In the NF2 protein and its close relatives, this domain is followed by a long alpha helical segment and a charged C terminal domain. Protein 4.1, the best studied member of the family, plays a critical role in maintaining membrane stability and cell shape in the erythrocyte by connecting integral membrane proteins, glycophorin, and the anion channel to the spectrin-actin lattice of the cytoskeleton. Protein 4.1 is the only other family member in which pathogenic variants are known (hereditary elliptocytosis).</p>
        <p>Two major alternative forms of the NF2 protein product exist. Isoform 1 is a protein of 595 amino acids produced from exons 1 through 15 and exon 17. Presence of the alternatively spliced exon 16 alters the C terminus of the protein, replacing 16 amino acids with 11 novel residues in isoform 2. Additional alternative splices predicting other minor species have also been described.</p>
        <p>Although the complete function of the NF2 protein remains elusive, recent studies suggest that &#x0201c;merlin&#x0201d; may coordinate the processes of growth-factor receptor signaling and cell adhesion. Varying use of this organizing activity by different types of cells could provide an explanation for the unique spectrum of tumors associated with NF2 deficiency in mammals [<xref ref-type="bibr" rid="nf2.REF.mcclatchey.2005.2265">McClatchey &#x00026; Giovannini 2005</xref>].</p>
        <p><bold>Abnormal gene product.</bold> Abnormal NF2 protein is caused by either a somatic or constitutional pathogenic variant.</p>
        <p>Attempts to identify truncated protein product have been unsuccessful in the main, although the non-truncated product from pathogenic missense variants may have partial function. It is thought that nonsense-mediated decay may account for the lack of identifiable product from most variant types; however, this does not explain why phenotypes are more severe for this type of variant than for whole-gene deletions.</p>
      </sec>
      <sec id="nf2.References">
        <title>References</title>
        <sec id="nf2.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="nf2.Literature_Cited.reflist0">
            <ref id="nf2.REF.aghi.2006.201">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aghi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kluwe</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Webster</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacoby</surname>
                    <given-names>LB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barker</surname>
                    <given-names>FG</given-names>
                    <suffix>2nd</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Ojemann</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mautner</surname>
                    <given-names>VF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacCollin</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Unilateral vestibular schwannoma with other neurofibromatosis type 2-related tumors: clinical and molecular study of a unique phenotype.</article-title>
                <source>J Neurosurg</source>
                <volume>104</volume>
                <fpage>201</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16509493</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.ammoun.2008.5236">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ammoun</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flaiz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ristic</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schuldt</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanemann</surname>
                    <given-names>CO</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.</article-title>
                <source>Cancer Res</source>
                <volume>68</volume>
                <fpage>5236</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">18593924</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.balasubramaniam.2007.447">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Balasubramaniam</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shannon</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hodaie</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laperriere</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michaels</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guha</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature.</article-title>
                <source>Neuro Oncol.</source>
                <volume>9</volume>
                <fpage>447</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">17704364</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.barbi.2002.e6">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Barbi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossier</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vossbeck</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hummler</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lang</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flock</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Terinde</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wirth</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vogel</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kehrer-Sawatzki</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Constitutional de novo interstitial deletion of 8 Mb on chromosome 22q12.1-12.3 encompassing the neurofibromatosis type 2 (NF2) locus in a dysmorphic girl with severe malformations.</article-title>
                <source>J Med Genet</source>
                <volume>39</volume>
                <fpage>E6</fpage>
                <pub-id pub-id-type="pmid">11836375</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.baser.2006.297">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baser</surname>
                    <given-names>ME</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene.</article-title>
                <source>Hum Mutat</source>
                <volume>27</volume>
                <fpage>297</fpage>
                <lpage>306</lpage>
                <pub-id pub-id-type="pmid">16521120</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.baser.2000.998">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baser</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jackler</surname>
                    <given-names>RK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sujansky</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubinstein</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Malignant peripheral nerve sheath tumours, radiotherapy and neurofibromatosis 2.</article-title>
                <source>Br J Cancer</source>
                <volume>82</volume>
                <fpage>998</fpage>
                <pub-id pub-id-type="pmid">10732777</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.baser.2002.715">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baser</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedman</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aeschliman</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joe</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramsden</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Predictors of the risk of mortality in neurofibromatosis 2.</article-title>
                <source>Am J Hum Genet</source>
                <volume>71</volume>
                <fpage>715</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">12235555</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.baser.2006.730">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baser</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedman</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Increasing the specificity of diagnostic criteria for schwannomatosis.</article-title>
                <source>Neurology</source>
                <volume>66</volume>
                <fpage>730</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">16534111</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.baser.2004.231">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baser</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuramoto</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joe</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedman</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gillespie</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramsden</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study.</article-title>
                <source>Am J Hum Genet</source>
                <volume>75</volume>
                <fpage>231</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15190457</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.baser.2005.540">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baser</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuramoto</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woods</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joe</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedman</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramsden</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olschwang</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bijlsma</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalamarides</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Papi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kato</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carroll</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lazaro</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joncourt</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parry</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2.</article-title>
                <source>J Med Genet</source>
                <volume>42</volume>
                <fpage>540</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15994874</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.blair.2011.308">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Blair</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kiang</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang-Rodriguez</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Doherty</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ongkeko</surname>
                    <given-names>WM</given-names>
                  </name>
                </person-group>
                <article-title>EGF and bFGF promote invasion that is modulated by PI3/Akt kinase and Erk in vestibular schwannoma.</article-title>
                <source>Otol Neurotol.</source>
                <year>2011</year>
                <volume>32</volume>
                <fpage>308</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">21178801</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.boyd.2008.358">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Boyd</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kluwe</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balogh</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maccollin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plotkin</surname>
                    <given-names>SR</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis.</article-title>
                <source>Clin Genet</source>
                <volume>74</volume>
                <fpage>358</fpage>
                <lpage>66</lpage>
                <pub-id pub-id-type="pmid">18647326</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.christiaans.2011.93">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Christiaans</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kenter</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brink</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Os</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baas</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Munckhof</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kidd</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hulsebos</surname>
                    <given-names>TJ</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas.</article-title>
                <source>J Med Genet.</source>
                <volume>48</volume>
                <fpage>93</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">20930055</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.cordeiro.2006.58">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cordeiro</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gardner</surname>
                    <given-names>KR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huson</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stewart</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elston</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Howard</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tullus</surname>
                    <given-names>KO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pike</surname>
                    <given-names>MG</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Renal vascular disease in neurofibromatosis type 2: association or coincidence?</article-title>
                <source>Dev Med Child Neurol</source>
                <volume>48</volume>
                <fpage>58</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16359595</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.dow.2005.574">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dow</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biggs</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gillespie</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramsden</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Spinal tumors in neurofibromatosis type 2. Is emerging knowledge of genotype predictive of natural history?</article-title>
                <source>J Neurosurg Spine</source>
                <volume>2</volume>
                <fpage>574</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15945431</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.evans.2009.599">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Neurofibromatosis 2</article-title>
                <comment>[Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]</comment>
                <source>Genet Med.</source>
                <volume>11</volume>
                <fpage>599</fpage>
                <lpage>610</lpage>
                <pub-id pub-id-type="pmid">19652604</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.evans.2005a.5">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baser</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Reilly</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rowe</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gleeson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saeed</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huson</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kerr</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Irving</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacFarlane</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferner</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLeod</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moffat</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramsden</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2005a</year>
                <article-title>Management of the patient and family with neurofibromatosis 2: a consensus conference statement.</article-title>
                <source>Br J Neurosurg</source>
                <volume>19</volume>
                <fpage>5</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">16147576</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.evans.1999.496">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Birch</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramsden</surname>
                    <given-names>RT</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Paediatric presentation of type 2 neurofibromatosis.</article-title>
                <source>Arch Dis Child</source>
                <volume>81</volume>
                <fpage>496</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10569966</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.evans.2006.289">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Birch</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramsden</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharif</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baser</surname>
                    <given-names>ME</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes.</article-title>
                <source>J Med Genet</source>
                <volume>43</volume>
                <fpage>289</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">16155191</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.evans.2010.327">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Howard</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giblin</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clancy</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spencer</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huson</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lalloo</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Birth incidence and prevalence of tumour prone syndromes: estimates from a UK genetic family register service.</article-title>
                <source>Am J Med Genet</source>
                <volume>152A</volume>
                <fpage>327</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">20082463</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.evans.1992.603">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huson</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donnai</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neary</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blair</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newton</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>1992</year>
                <article-title>A clinical study of type 2 neurofibromatosis.</article-title>
                <source>Q J Med</source>
                <volume>84</volume>
                <fpage>603</fpage>
                <lpage>18</lpage>
                <pub-id pub-id-type="pmid">1484939</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.evans.2009.5032">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalamarides</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hunter-Schaedle</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blakeley</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Babovic-Vuskanovic</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Belzberg</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bollag</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiTomaso</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Golfinos</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacob</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalpana</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karajannis</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korf</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurzrock</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Law</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McClatchey</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Packer</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roehm</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubenstein</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Slattery</surname>
                    <given-names>W</given-names>
                    <suffix>3rd</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Tonsgard</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Welling</surname>
                    <given-names>DB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Widemann</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yohay</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giovannini</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.</article-title>
                <source>Clin Cancer Res.</source>
                <volume>15</volume>
                <fpage>5032</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">19671848</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.evans.2005b.93">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moran</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saeed</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gurusinghe</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramsden</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2005b</year>
                <article-title>Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought.</article-title>
                <source>Otol Neurotol</source>
                <volume>26</volume>
                <fpage>93</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15699726</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.evans.2007a.354">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramsden</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gokhale</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowers</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huson</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007a</year>
                <article-title>Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma?</article-title>
                <source>Clin Genet</source>
                <volume>71</volume>
                <fpage>354</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">17470137</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.evans.2007b.424">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramsden</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shenton</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gokhale</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowers</surname>
                    <given-names>NL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huson</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pichert</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007b</year>
                <article-title>Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification.</article-title>
                <source>J Med Genet</source>
                <volume>44</volume>
                <fpage>424</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">17307835</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.evans.2008.92">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramsden</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shenton</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gokhale</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowers</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huson</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>AJ</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>What are the implications in individuals with unilateral vestibular schwannoma and other neurogenic tumors?</article-title>
                <source>J Neurosurg</source>
                <volume>108</volume>
                <fpage>92</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">18173316</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.evans.2000.897">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sainio</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baser</surname>
                    <given-names>ME</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Neurofibromatosis type 2.</article-title>
                <source>J Med Genet</source>
                <volume>37</volume>
                <fpage>897</fpage>
                <lpage>904</lpage>
                <pub-id pub-id-type="pmid">11106352</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.evans.1998a.450">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trueman</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strachan</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>1998a</year>
                <article-title>Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations.</article-title>
                <source>J Med Genet</source>
                <volume>35</volume>
                <fpage>450</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">9643284</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.evans.1998b.727">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trueman</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramsden</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strachan</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>1998b</year>
                <article-title>Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis.</article-title>
                <source>Am J Hum Genet</source>
                <volume>63</volume>
                <fpage>727</fpage>
                <lpage>36</lpage>
                <pub-id pub-id-type="pmid">9718334</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.evans.2005c.45">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watson</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baser</surname>
                    <given-names>ME</given-names>
                  </name>
                </person-group>
                <year>2005c</year>
                <article-title>Multiple meningiomas: differential involvement of the NF2 gene in children and adults.</article-title>
                <source>J Med Genet</source>
                <volume>42</volume>
                <fpage>45</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15635074</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.feucht.2008.882">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Feucht</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griffiths</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niem&#x000fc;ller</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haase</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richard</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mautner</surname>
                    <given-names>VF</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Neurofibromatosis 2 leads to higher incidence of strabismological and neuro-ophthalmological disorders.</article-title>
                <source>Acta Ophthalmol</source>
                <volume>86</volume>
                <fpage>882</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">18976311</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.goutagny.2010.341">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Goutagny</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalamarides</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Meningiomas and neurofibromatosis.</article-title>
                <source>J Neurooncol.</source>
                <volume>99</volume>
                <fpage>341</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">20714782</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.hadfield.2008.332">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hadfield</surname>
                    <given-names>KD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newman</surname>
                    <given-names>WG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowers</surname>
                    <given-names>NL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bolger</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colley</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCann</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trump</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prescott</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis.</article-title>
                <source>J Med Genet</source>
                <volume>45</volume>
                <fpage>332</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18285426</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.hadfield.2010.567">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hadfield</surname>
                    <given-names>KD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trump</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newman</surname>
                    <given-names>WG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>SMARCB1 mutations are not a common cause of multiple meningiomas.</article-title>
                <source>J Med Genet</source>
                <volume>47</volume>
                <fpage>567</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">20472658</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.hagel.2002.179">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hagel</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindenau</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamszus</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kluwe</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stavrou</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mautner</surname>
                    <given-names>VF</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Polyneuropathy in neurofibromatosis 2: clinical findings, molecular genetics and neuropathological alterations in sural nerve biopsy specimens.</article-title>
                <source>Acta Neuropathol (Berl)</source>
                <volume>104</volume>
                <fpage>179</fpage>
                <lpage>87</lpage>
                <pub-id pub-id-type="pmid">12111361</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.hanemann.2008.606">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hanemann</surname>
                    <given-names>CO</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Magic but treatable? Tumours due to loss of merlin.</article-title>
                <source>Brain</source>
                <volume>131</volume>
                <fpage>606</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">17940085</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.hirokawa.2004.20">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hirokawa</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tikoo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huynh</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Utermark</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanemann</surname>
                    <given-names>CO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giovannini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xiao</surname>
                    <given-names>GH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Testa</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maruta</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor.</article-title>
                <source>Cancer J</source>
                <volume>10</volume>
                <fpage>20</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15000491</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.hulsebos.2007.805">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hulsebos</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plomp</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolterman</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robanus-Maandag</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baas</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wesseling</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Germline mutation of INI1/SMARCB1 in familial schwannomatosis.</article-title>
                <source>Am J Hum Genet.</source>
                <volume>80</volume>
                <fpage>805</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">17357086</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.kluwe.1998.228">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kluwe</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacCollin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tatagiba</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hazim</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haase</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mautner</surname>
                    <given-names>VF</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Phenotypic variability associated with 14 splice-site mutations in the NF2 gene.</article-title>
                <source>Am J Med Genet</source>
                <volume>77</volume>
                <fpage>228</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">9605590</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.kluwe.2003.109">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kluwe</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mautner</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heinrich</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dezube</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacoby</surname>
                    <given-names>LB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedrich</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacCollin</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas.</article-title>
                <source>J Med Genet</source>
                <volume>40</volume>
                <fpage>109</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">12566519</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.kluwe.2005.384">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kluwe</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nygren</surname>
                    <given-names>AO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Errami</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heinrich</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matthies</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tatagiba</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mautner</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Screening for large mutations of the NF2 gene.</article-title>
                <source>Genes Chromosomes Cancer</source>
                <volume>42</volume>
                <fpage>384</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">15645494</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.kros.2001.367">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kros</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Greve</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Tilborg</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hop</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pieterman</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Avezaat</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lekanne Dit Deprez</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zwarthoff</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>NF2 status of meningiomas is associated with tumour localization and histology.</article-title>
                <source>J Pathol</source>
                <volume>194</volume>
                <fpage>367</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">11439370</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.legoix.2000.62">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Legoix</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarkissian</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cazes</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giraud</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sor</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lenoir</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zucman-Rossi</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Molecular characterization of germline NF2 gene rearrangements.</article-title>
                <source>Genomics</source>
                <volume>65</volume>
                <fpage>62</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">10777666</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.lomas.2005.314">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lomas</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bello</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arjona</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alonso</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinez-Glez</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lopez-Marin</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aminoso</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Campos</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Isla</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vaquero</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rey</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Genetic and epigenetic alteration of the NF2 gene in sporadic meningiomas.</article-title>
                <source>Genes Chromosomes Cancer</source>
                <volume>42</volume>
                <fpage>314</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15609345</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.maccollin.2005.1838">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>MacCollin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiocca</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedman</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horvitz</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaramillo</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lev</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mautner</surname>
                    <given-names>VF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niimura</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plotkin</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sang</surname>
                    <given-names>CN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stemmer-Rachamimov</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roach</surname>
                    <given-names>ES</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Diagnostic criteria for schwannomatosis.</article-title>
                <source>Neurology</source>
                <volume>64</volume>
                <fpage>1838</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">15955931</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.maccollin.2003.1968">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>MacCollin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willett</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heinrich</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacoby</surname>
                    <given-names>LB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Acierno</surname>
                    <given-names>JS</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Perry</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Louis</surname>
                    <given-names>DN</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Familial schwannomatosis: Exclusion of the NF2 locus as the germline event.</article-title>
                <source>Neurology</source>
                <volume>60</volume>
                <fpage>1968</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">12821741</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.mantripragada.2003.615">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mantripragada</surname>
                    <given-names>KK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buckley</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benetkiewicz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Bustos</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirvela</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jarbo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruder</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wensman</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mathiesen</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nyberg</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Papi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>VP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ichimura</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dumanski</surname>
                    <given-names>JP</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>High-resolution profiling of an 11 Mb segment of human chromosome 22 in sporadic schwannoma using array-CGH.</article-title>
                <source>Int J Oncol</source>
                <volume>22</volume>
                <fpage>615</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">12579316</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.masuda.2004.150">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Masuda</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fisher</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oppenheimer</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iqbal</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Slattery</surname>
                    <given-names>WH</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Hearing changes after diagnosis in neurofibromatosis type 2.</article-title>
                <source>Otol Neurotol</source>
                <volume>25</volume>
                <fpage>150</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">15021775</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.maxwell.1998.562">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Maxwell</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shih</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galanopoulos</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hedley-Whyte</surname>
                    <given-names>ET</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cosgrove</surname>
                    <given-names>GR</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Familial meningioma: analysis of expression of neurofibromatosis 2 protein Merlin. Report of two cases.</article-title>
                <source>J Neurosurg</source>
                <volume>88</volume>
                <fpage>562</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">9488313</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.mcclatchey.2005.2265">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McClatchey</surname>
                    <given-names>AI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giovannini</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin.</article-title>
                <source>Genes Dev</source>
                <volume>19</volume>
                <fpage>2265</fpage>
                <lpage>77</lpage>
                <pub-id pub-id-type="pmid">16204178</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.mohyuddin.2002.315">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mohyuddin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neary</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Purcell</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reid</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramsden</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Read</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Black</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas.</article-title>
                <source>J Med Genet.</source>
                <volume>39</volume>
                <fpage>315</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">12011146</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.moyhuddin.2003.459">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Moyhuddin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baser</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watson</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Purcell</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramsden</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heiberg</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring.</article-title>
                <source>J Med Genet.</source>
                <volume>40</volume>
                <fpage>459</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">12807969</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.nguyen.2005.247">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nguyen</surname>
                    <given-names>DQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chatterjee</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bates</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Persistent hyperplastic primary vitreous in association with neurofibromatosis 2.</article-title>
                <source>J Pediatr Ophthalmol Strabismus</source>
                <volume>42</volume>
                <fpage>247</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16121558</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.patronas.2001.434">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Patronas</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Courcoutsakis</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bromley</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Katzman</surname>
                    <given-names>GL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacCollin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parry</surname>
                    <given-names>DM</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype.</article-title>
                <source>Radiology</source>
                <volume>218</volume>
                <fpage>434</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">11161159</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.perry.2001.994">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Perry</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giannini</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raghavan</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scheithauer</surname>
                    <given-names>BW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Banerjee</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Margraf</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowers</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lytle</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newsham</surname>
                    <given-names>IF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gutmann</surname>
                    <given-names>DH</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases.</article-title>
                <source>J Neuropathol Exp Neurol</source>
                <volume>60</volume>
                <fpage>994</fpage>
                <lpage>1003</lpage>
                <pub-id pub-id-type="pmid">11589430</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.plotkin.2008.487">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Plotkin</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singh</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Donnell</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McClatchey</surname>
                    <given-names>AI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halpin</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.</article-title>
                <source>Nat Clin Pract Oncol</source>
                <volume>5</volume>
                <fpage>487</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">18560388</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.plotkin.2009.358">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Plotkin</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stemmer-Rachamimov</surname>
                    <given-names>AO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barker</surname>
                    <given-names>FG</given-names>
                    <suffix>2nd</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Halpin</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Padera</surname>
                    <given-names>TP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tyrrell</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sorensen</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jain</surname>
                    <given-names>RK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>di Tomaso</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.</article-title>
                <source>N Engl J Med.</source>
                <volume>361</volume>
                <fpage>358</fpage>
                <lpage>67</lpage>
                <pub-id pub-id-type="pmid">19587327</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.rowe.2003.1288">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rowe</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Radatz</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walton</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soanes</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodgers</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kemeny</surname>
                    <given-names>AA</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis.</article-title>
                <source>J Neurol Neurosurg Psychiatry</source>
                <volume>74</volume>
                <fpage>1288</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">12933938</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.ruggieri.2005.21">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ruggieri</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iannetti</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Polizzi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>La Mantia</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spalice</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giliberto</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Platania</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gabriele</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Albanese</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pavone</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients.</article-title>
                <source>Neuropediatrics</source>
                <volume>36</volume>
                <fpage>21</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">15776319</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.sakai.2005.332">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sakai</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vallejo</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shannon</surname>
                    <given-names>KT</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>A parturient with neurofibromatosis type 2: anesthetic and obstetric considerations for delivery.</article-title>
                <source>Int J Obstet Anesth</source>
                <volume>14</volume>
                <fpage>332</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16140520</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.sestini.2008.227">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sestini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bacci</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Provenzano</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Genuardi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Papi</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas.</article-title>
                <source>Hum Mutat</source>
                <volume>29</volume>
                <fpage>227</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">18072270</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.slattery.2004.811">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Slattery</surname>
                    <given-names>WH</given-names>
                    <suffix>3rd</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Fisher</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iqbal</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oppenhiemer</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects.</article-title>
                <source>Otol Neurotol</source>
                <volume>25</volume>
                <fpage>811</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15354016</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.smith.2011.261">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Higgs</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bowers</surname>
                    <given-names>NL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halliday</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patterson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gillespie</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huson</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freeman</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lloyd</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rutherford</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramsden</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Cranial meningiomas in 411 NF2 patients with proven gene mutations: Clear positional effect of mutations, but absence of female severity effect on age at onset.</article-title>
                <source>J Med Genet</source>
                <volume>48</volume>
                <fpage>261</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">21278391</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.sperfeld.2002.996">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sperfeld</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hein</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schroder</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ludolph</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanemann</surname>
                    <given-names>CO</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2.</article-title>
                <source>Brain</source>
                <volume>125</volume>
                <fpage>996</fpage>
                <lpage>1004</lpage>
                <pub-id pub-id-type="pmid">11960890</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.spiegel.2005.336">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Spiegel</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hapgood</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hess</surname>
                    <given-names>PE</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Epidural anesthesia in a parturient with neurofibromatosis type 2 undergoing cesarean section.</article-title>
                <source>Int J Obstet Anesth</source>
                <volume>14</volume>
                <fpage>336</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16154348</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.szijan.2003.41">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Szijan</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rochefort</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruder</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Surace</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Machiavelli</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dalamon</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cotignola</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferreiro</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campero</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Basso</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dumanski</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouleau</surname>
                    <given-names>GA</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>NF2 tumor suppressor gene: a comprehensive and efficient detection of somatic mutations by denaturing HPLC and microarray-CGH.</article-title>
                <source>Neuromolecular Med</source>
                <volume>3</volume>
                <fpage>41</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">12665675</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.tsilchorozidou.2004.529">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tsilchorozidou</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Menko</surname>
                    <given-names>FH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lalloo</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kidd</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Silva</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malcolmson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dore</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Madan</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yovos</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsaligopoulos</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vogiatzis</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baser</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Constitutional rearrangements of chromosome 22 as a cause of neurofibromatosis 2.</article-title>
                <source>J Med Genet</source>
                <volume>41</volume>
                <fpage>529</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">15235024</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.wallace.2004.368">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watson</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oward</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elles</surname>
                    <given-names>RG</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Mutation scanning of the NF2 gene: an improved service based on meta-PCR/sequencing, dosage analysis, and loss of heterozygosity analysis.</article-title>
                <source>Genet Test</source>
                <volume>8</volume>
                <fpage>368</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">15684865</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.zucmanrossi.1998.2095">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zucman-Rossi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Legoix</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Der Sarkissian</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheret</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sor</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernardi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cazes</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giraud</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ollagnon</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lenoir</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>NF2 gene in neurofibromatosis type 2 patients.</article-title>
                <source>Hum Mol Genet</source>
                <volume>7</volume>
                <fpage>2095</fpage>
                <lpage>101</lpage>
                <pub-id pub-id-type="pmid">9817927</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="nf2.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="nf2.Suggested_Reading.reflist0">
            <ref id="nf2.REF.hanemann.2006.1533">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hanemann</surname>
                    <given-names>CO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evans</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>News on the genetics, epidemiology, medical care and translational research of Schwannomas.</article-title>
                <source>J Neurol</source>
                <volume>253</volume>
                <fpage>1533</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">17219030</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.houshmandi.2007.811">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Houshmandi</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gutmann</surname>
                    <given-names>DH</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>All in the family: using inherited cancer syndromes to understand de-regulated cell signaling in brain tumors.</article-title>
                <source>J Cell Biochem</source>
                <volume>102</volume>
                <fpage>811</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">17721931</pub-id>
              </element-citation>
            </ref>
            <ref id="nf2.REF.maccollin">
              <mixed-citation publication-type="web">MacCollin M, Gusella J. Neurofibromatosis 2. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID).</italic> Chapter 40. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ommbid.mhmedical.com/">online</ext-link>.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="nf2.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="nf2.Author_History">
          <title>Author History</title>
          <p>D Gareth Evans, MD, FRCP (2004-present)Mia MacCollin, MD; Harvard Medical School (1998-2004)</p>
        </sec>
        <sec id="nf2.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>18 August 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>19 May 2009 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>6 June 2006 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>6 April 2004 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>29 October 2001 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>14 October 1998 (pb) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>5 August 1998 (mm) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="nf2.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>The position of pathogenic variants in <italic toggle="yes">NF2</italic> affects the likelihood of developing a meningioma.
A. The Kaplan-Meier plot shows the risk of meningioma within each functional domain. Gene regions are divided into exons 1-3, 4-6, 7-9, 10-13, and 14-15. B. The bar graph shows the overall risk for meningioma conferred by pathogenic variants in individual exons. 5&#x02032; regions confer a higher risk than 3&#x02032; regions and exons encoding the junctions between functional domains confer a higher relative risk than the rest of the domain.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nf2-Image001" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
